Welcome to our dedicated page for Hemogenyx Pharma news (Ticker: HOPHF), a resource for investors and traders seeking the latest updates and insights on Hemogenyx Pharma stock.
Hemogenyx Pharma PLC (HOPHF), associated with Hemogenyx Pharmaceuticals plc (LSE: HEMO), generates news primarily around its clinical development, financing, and strategic collaboration activities in biotechnology. The company describes itself as a clinical stage biopharmaceutical group developing new medicines and treatments for blood and autoimmune diseases, with a particular focus on its HG-CT-1 CAR-T cell therapy for relapsed or refractory acute myeloid leukemia (R/R AML).
News updates frequently cover milestones in the Phase I clinical trial of HG-CT-1, including first-in-human dosing, safety evaluations, early signs of efficacy, and decisions by the independent Data Safety Monitoring Board on dose escalation. Additional coverage includes regulatory developments such as FDA interactions, Institutional Review Board approvals for pediatric enrollment, and broader trial design updates for both adult and pediatric patients.
Hemogenyx Pharmaceuticals also issues announcements on operational and strategic initiatives, such as its manufacturing partnership with Made Scientific to support HG-CT-1 production and its letter of intent with Cellin Technologies in Estonia to explore commercialization under the hospital exemption pathway. Capital markets news includes publication of a prospectus, share issuances arising from warrant exercises and restricted stock units, and updates on admission of new shares to the Official List and to trading on the London Stock Exchange.
Visitors to this news page can review a stream of company disclosures that document clinical progress, financing activities, manufacturing arrangements, and potential early revenue pathways. For investors and observers interested in CAR-T therapies, hematology-oncology, and early-stage biopharmaceutical development, Hemogenyx-related news provides insight into how the company is advancing its lead program and supporting infrastructure over time.
Hemogenyx Pharmaceuticals (LSE:HEMO) has signed a Letter of Intent (LOI) with Cellin Technologies to explore the commercialization of its HG-CT-1 CAR-T cell therapy for relapsed/refractory acute myeloid leukemia (R/R AML) in Estonia. The collaboration leverages Estonia's hospital exemption pathway, which allows use of unauthorized advanced therapy medicinal products with sufficient preclinical or Phase I data.
This partnership represents Hemogenyx's first potential near-term revenue opportunity for HG-CT-1. Under the LOI, Hemogenyx retains full intellectual property rights while Cellin provides local manufacturing, regulatory, and operational support. The arrangement also enables treatment cost reimbursement through Estonia's National Health Fund while generating valuable real-world clinical data alongside the ongoing Phase I trial.
Hemogenyx Pharmaceuticals (HOPHF) has announced successful safety evaluation of the third patient treated with HG-CT-1, their proprietary CAR-T therapy for relapsed/refractory acute myeloid leukemia (R/R AML) in adults. The Phase I clinical trial has shown promising early results, with the treatment being well-tolerated and meeting predefined safety criteria.
Early efficacy signals were observed as AML cells became undetectable using standard testing methods. The Data Safety Monitoring Board (DSMB) will review safety data from the first three patients treated at the lowest dose to determine if dose escalation can proceed. The trial includes secondary endpoints focusing on efficacy, overall survival, progression-free survival, and duration of response.
Hemogenyx Pharmaceuticals (OTCQB:HOPHF) has been invited to present at the prestigious DCNY Summit, taking place in Washington, DC on September 18, 2025, and in New York on September 22, 2025. The summit, co-hosted by the Alliance Indus Foundation and various international partners, brings together policymakers, investors, and corporate leaders.
During the event, Hemogenyx will showcase its clinical progress, including updates on its Phase I clinical trial of CAR-T cell therapy for acute myeloid leukemia (AML). The company will have the opportunity to engage with key stakeholders and potential investors, as the summit has previously helped participants secure significant growth capital.
Hemogenyx Pharmaceuticals (HOPHF) has announced a strategic manufacturing partnership with Made Scientific to advance its HG-CT-1 CAR-T therapy for relapsed/refractory acute myeloid leukemia (r/r AML) in adults. The collaboration will utilize Made Scientific's GMP facilities in Newark and Princeton, NJ, for both clinical and commercial supply of cell therapies.
The partnership aims to accelerate Hemogenyx's ongoing Phase I clinical trial of HG-CT-1 and potentially expand to include pediatric r/r AML patients. Early clinical data has shown promising results in both safety and potential efficacy. Made Scientific will provide specialized expertise in CAR-T cell therapy technology transfer and manufacturing support.
Hemogenyx Pharmaceuticals (LSE:HEMO) has announced the exercise of warrants for 67,371 new ordinary shares. The warrants, originally granted on March 11, 2025, have generated subscription monies of £235,799 for the company.
The Warrant Shares will be admitted to trading on the LSE's main market on September 10, 2025. Following admission and including the previously announced 250,000 new ordinary shares, the company's total issued shares and voting rights will increase to 5,361,267.
Hemogenyx Pharmaceuticals (LSE:HEMO) announced the exercise of warrants for 250,000 new ordinary shares. The warrants, originally granted on May 8, 2025, had their exercise price adjusted to 180p per share, resulting in subscription monies of £450,000 received by the company.
Following admission of these shares and including the previously announced 316,667 new ordinary shares from August 26, 2025, the company's total issued shares and voting rights will increase to 5,293,896. The new shares are expected to be admitted to trading on the LSE main market on September 9, 2025.
Hemogenyx Pharmaceuticals (OTC:HOPHF) has secured £620,000 in funding through the issuance of convertible loan notes (CLNs) to support its ongoing clinical trial of HG-CT-1, a CAR-T cell therapy for relapsed or refractory acute myeloid leukemia.
The CLNs were issued at a fixed conversion price of £5.30 per share and are non-interest bearing. They will automatically convert into 116,982 Ordinary Shares following an increase in the Company's headroom restrictions under FCA's Prospectus Rules, expected around November 15, 2025.
Hemogenyx Pharmaceuticals (LSE: HEMO) has announced its decision to re-appoint PKF Littlejohn LLP as its external auditor for the financial year ending December 2025 and beyond. The decision follows a mandatory audit tender process required for public interest entities every ten years. The appointment will coincide with the mandatory lead audit partner rotation and requires shareholder approval at the company's 2026 Annual General Meeting.
The clinical-stage biopharmaceutical company, headquartered in London with US subsidiaries in New York City, focuses on developing treatments for blood and autoimmune diseases. The audit tender process was overseen by the Audit Committee, with detailed evaluation criteria to be disclosed in the Group's 2025 Annual Report & Accounts.
Hemogenyx Pharmaceuticals (LSE:HEMO) has successfully raised £570,000 through an allotment of 316,667 new ordinary shares at 180p per share, representing a premium to the market price. The shares were initially subscribed by CEO Vladislav Sandler and will be directed to a small group of investors.
The funding will support the continuation of the company's Phase I clinical trials for HG-CT-1, a Chimeric Antigen Receptor T-cell therapy targeting relapsed/refractory acute myeloid leukemia in adults. The investors will also receive one-for-one warrants exercisable for 36 months at 180p.
Following admission, expected around September 4, 2025, the company's total issued shares will be 5,043,896. The premium-priced fundraising reflects investor confidence in Hemogenyx's progress and long-term prospects.
Hemogenyx Pharmaceuticals (LSE:HEMO, OTC:HOPHF) has successfully treated the third patient in its Phase I clinical trial of HG-CT-1, a proprietary CAR-T cell therapy for relapsed/refractory acute myeloid leukemia (R/R AML). This marks the completion of the first adult dose cohort, achieved after receiving special FDA permission under exceptional circumstances.
The company reported encouraging early results, with the first two patients remaining alive at six and three months post-treatment. Following this milestone, Hemogenyx plans to advance to a second adult dose cohort with twice the initial dose and initiate a pediatric trial arm. The Phase I trial aims to evaluate safety and secondary endpoints including anti-leukemic activity, survival rates, and duration of response.